lunes, 30 de enero de 2017

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer | BMC Cancer | Full Text

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer | BMC Cancer | Full Text

Biomed Central



BMC Cancer

Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer

BMC Cancer201616:850
DOI: 10.1186/s12885-016-2886-9
Received: 5 August 2016
Accepted: 25 October 2016
Published: 5 November 2016

Abstract

Background

The rapidly expanding arsenal of chemotherapeutic agents approved in the past 5 years represents significant progress in the field. However, this poses a challenge for oncologists to choose which drug or combination of drugs is best for any individual. Because only a fraction of patients respond to any drug, efforts have been made to devise strategies to personalize care. The majority of efforts have involved development of predictive biomarkers. While there are notable successes, there are no predictive biomarkers for most drugs. Moreover, predictive biomarkers enrich the cohort of individuals likely to benefit; they do not guarantee benefit.

Main text

There is a need to devise alternate strategies to tailor cancer care. One alternative approach is to enhance the current adaptive approach, which involves administration of a drug and cessation of treatment once progression is documented. This currently involves radiographic tests for the most part, which are expensive, inconvenient and imperfect in their ability to categorize patients who are and are not benefiting from treatment. A biomarker approach to categorizing response may have advantages.

Conclusion

Herein, we discuss the state of the art on treatment response assessment. While the most mature technologies for response assessment involve radiographic tests such as CT and PET, reports are emerging on biomarkers used to monitor therapeutic efficacy. Potentially, response biomarkers represent a less expensive and more convenient means of monitoring therapy, although an ideal response biomarker has not yet been described. A framework for future response biomarker discovery is described.

Keywords

Response Biomarker Predictive biomarker RECIST Assessing response Adaptive biomarker Systemic therapy Cancer

No hay comentarios:

Publicar un comentario